GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Valuation Rank

IGC Pharma (FRA:IGS1) Valuation Rank


View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

IGC Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (FRA:IGS1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Valuation Rank
Comparable Companies
PLUR PMN PTN SRZN HRGN AURX RNXT BOLT NKGN ICCC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IGC:USA IGS1:Germany
Address
10224 Falls Road, Potomac, MD, USA, 20854
Website
https://www.igcinc.us
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.